Gene Inger’s Trading Notebook: Why retailers like Nordstrom, Walmart and Home Depot are flat a...
The New GM
08/14/2015 8:00 am EST
With the market dramatically bifurcated and commodities and interest rate-sensitive investments underperforming, we’re going fishing in the value pond with our latest recommendation, suggests income expert Chloe Lutts Jensen, editor of Cabot Dividend Investor.
General Motors (GM) is an undervalued company in the midst of a turnaround.
The automaker is a household name in the US, but these days the stock is associated more with the 2008 auto industry bailout than with its past as a must-own blue chip. But GM has changed since the bailout.
It has grown revenues in every year of the past five, averaging 4% growth per year. Most recently, low gas prices have driven consumers back to GM’s trucks and SUVs, boosting sales and margins.
In the second quarter of 2015, adjusted EPS grew 122% year-over-year, beating analyst estimates by nearly 20%.
Analysts are still concerned about the slowdown in China. Also weighing on the stock is the US Justice Department’s investigation into how GM handled recalls of cars with faulty ignition switches last year. The case could result in GM facing a monetary settlement of over $1 billion.
The stock’s current P/E ratio is under 12, while its forward P/E is in the basement at less than 7. And the price-to-book ratio is very reasonable at only 1.4.
The new GM is still young and somewhat unpredictable and the company’s turnaround plan is still in progress. However, the current yield of 4.6% makes it easy to wait for investors to start coming back to this name.
The new, post-bailout company declared its first dividend in January 2014 and has paid six quarterly dividends to date, raising the dividend for the first time this past April.
Investors with high risk tolerance who value high current yields and high potential for long-term capital appreciation and dividend growth can buy at current levels.
More from MoneyShow.com:
Related Articles on STOCKS
When we recommended pharmaceutical giant AbbVie (ABBV) this past June, it had recently raised its qu...
Eli Lilly (LLY) manufactures drugs to treat pain, diabetes, and cancer. It also produces animal heal...
Verisk Analytics (VRSK) has broken out of a nine-week, classic double bottom base. The move carries ...